ストックスクリーナーアプリを入手
17.23
0.29%
0.05
アフターアワーズ：
17.00
-0.23
-1.33%
前日終値:
$17.18
開ける：
$17.22
24時間の取引高:
36,344
Relative Volume:
0.57
時価総額：
$124.23M
収益：
$100.44M
当期純損益:
$-133.16M
株価収益率:
-0.6689
EPS:
-25.76
ネットキャッシュフロー:
$-94.85M
1週間 パフォーマンス:
-3.31%
1か月 パフォーマンス:
+28.01%
6か月 パフォーマンス:
+114.84%
1年 パフォーマンス:
+75.64%
1日の値動き範囲:
$17.12
$17.80
1週間の範囲:
$16.65
$18.25
52週間の値動き範囲:
$5.005
$18.70
Atara Biotherapeutics Inc Stock (ATRA) Company Profile
名前
Atara Biotherapeutics Inc
セクター
電話
805-623-4211
住所
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
ATRA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ATRA
Atara Biotherapeutics Inc
|
17.23 | 123.87M | 100.44M | -133.16M | -94.85M | -25.76 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.38 | 114.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
748.71 | 78.80B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
396.04 | 51.80B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
847.05 | 53.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
166.55 | 42.33B | 447.02M | -1.18B | -906.14M | -6.1812 |
Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-11-09 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2023-11-09 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-11-09 | ダウングレード | Mizuho | Buy → Neutral |
| 2022-07-20 | ダウングレード | Citigroup | Neutral → Sell |
| 2022-07-13 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-07-13 | ダウングレード | Stifel | Buy → Hold |
| 2022-05-10 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-05-13 | アップグレード | JP Morgan | Neutral → Overweight |
| 2020-12-09 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-12-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-11-10 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-06-30 | 開始されました | Evercore ISI | Outperform |
| 2020-06-15 | 開始されました | H.C. Wainwright | Buy |
| 2020-04-23 | アップグレード | Citigroup | Neutral → Buy |
| 2019-11-08 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-09-27 | ダウングレード | Goldman | Neutral → Sell |
| 2019-09-16 | ダウングレード | Jefferies | Buy → Hold |
| 2019-06-04 | アップグレード | Citigroup | Sell → Neutral |
| 2019-05-30 | 開始されました | ROTH Capital | Buy |
| 2019-05-23 | 開始されました | Stifel | Buy |
| 2019-01-23 | 開始されました | Mizuho | Buy |
| 2018-04-10 | 開始されました | JP Morgan | Overweight |
| 2018-03-16 | 開始されました | Guggenheim | Neutral |
| 2018-03-05 | 繰り返されました | Jefferies | Buy |
| 2018-02-28 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-02-15 | ダウングレード | Citigroup | Neutral → Sell |
| 2018-01-03 | アップグレード | Citigroup | Sell → Neutral |
| 2017-10-06 | 再開されました | Goldman | Neutral |
すべてを表示
Atara Biotherapeutics Inc (ATRA) 最新ニュース
Is Atara Biotherapeutics Inc. stock a good choice for value investorsJuly 2025 Retail & Real-Time Volume Analysis Alerts - Улправда
(ATRA) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
Is Atara's Tab-Cel The Missing Piece In A Difficult-To-Treat Cancer? - RTTNews
Panic Selling: Why Atara Biotherapeutics Inc stock could be next big winner2025 Buyback Activity & Fast Momentum Stock Entry Tips - moha.gov.vn
Atara Biotherapeutics Stock Drop Looks Sharp, But How Deep Can It Go? - Trefis
Would You Still Hold Atara Biotherapeutics Stock If It Fell Another 30%? - Trefis
Can Atara Biotherapeutics Stock Recover If Markets Fall? - Trefis
How Atara Biotherapeutics Inc. stock performs during Fed tightening cyclesWeekly Investment Report & Weekly Watchlist of Top Performers - Newser
Can Atara Biotherapeutics Inc. (AT20) stock hit consensus price targetsJuly 2025 Closing Moves & Daily Profit Maximizing Trade Tips - Newser
Is Atara Biotherapeutics Inc. (AT20) stock trading at attractive multiplesJuly 2025 Catalysts & Scalable Portfolio Growth Ideas - Newser
Why Atara Biotherapeutics Inc. (AT20) stock gets analyst attentionPortfolio Gains Summary & Daily Growth Stock Investment Tips - Newser
Is Confidence Futuristic Energetech Limited a Top Alpha Generator for Growth PortfoliosMarket Correction Analysis & Free Real-Time Trading Signals - earlytimes.in
Can Atara Biotherapeutics Inc. stock maintain operating margins2025 Key Lessons & Reliable Breakout Forecasts - Newser
Atara Biotherapeutics (ATRA) Stock Analysis Report | Financials & Insights - Benzinga
Atara Biotherapeutics (NASDAQ:ATRA) Stock Price Passes Below 50 Day Moving AverageHere's Why - MarketBeat
Why Atara Biotherapeutics Inc. (AT20) stock could rally strongly2025 Major Catalysts & Breakout Confirmation Trade Signals - Newser
How robust is Atara Biotherapeutics Inc. (AT20) stock financial positionPortfolio Growth Summary & Accurate Entry and Exit Point Alerts - Newser
Why analysts remain bullish on Atara Biotherapeutics Inc. stockTrade Analysis Report & Expert Curated Trade Setup Alerts - Newser
Can Atara Biotherapeutics Inc. (AT20) stock sustain revenue momentum2025 Trading Recap & Free Long-Term Investment Growth Plans - Newser
Is Atara Biotherapeutics Inc. stock attractive for long term wealth buildingQuarterly Risk Review & Expert Verified Movement Alerts - Newser
Will Atara Biotherapeutics Inc. (AT20) stock benefit from infrastructure billJuly 2025 PostEarnings & Verified Short-Term Plans - Newser
Atara Biotherapeutics: An Empty Pipeline With Little Gas (NASDAQ:ATRA) - Seeking Alpha
Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) (PR Newswire) - Aktiellt
Perre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc. (PR Newswire) - Aktiellt
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives $21.00 Consensus Target Price from Analysts - Defense World
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Understanding the Setup: (ATRA) and Scalable Risk - news.stocktradersdaily.com
Mizuho raises Atara Biotherapeutics stock price target on reduced expenses By Investing.com - Investing.com Canada
Atara Biotherapeutics Inc Stock Analysis and ForecastEconomic Indicators Overview & Chat With Other Investors on Daily Signals - earlytimes.in
Is Atara Biotherapeutics Inc a good long term investmentCup and Handle Formations & Budget Friendly Portfolio Growth - earlytimes.in
Mizuho Raises Price Target on Atara Biotherapeutics to $18 From $16, Keeps Outperform Rating - MarketScreener
Will Atara Biotherapeutics Inc. (AT20) stock keep high P E multiplesTrade Risk Assessment & Verified Swing Trading Watchlists - newser.com
Will Atara Biotherapeutics Inc. (AT20) stock sustain uptrend momentumJuly 2025 Opening Moves & Daily Momentum Trading Reports - newser.com
Why Atara Biotherapeutics Inc. stock could see breakout soon2025 Year in Review & Expert Verified Movement Alerts - newser.com
Atara biotherapeutics CEO Nguyen sells $38437 in stock By Investing.com - Investing.com Canada
Can machine learning forecast Atara Biotherapeutics Inc. recoveryMarket Movement Recap & Low Risk Investment Opportunities - newser.com
Is Atara Biotherapeutics Inc. (AT20) stock attractive post correctionMarket Growth Review & Weekly Market Pulse Alerts - newser.com
How Atara Biotherapeutics Inc. (AT20) stock benefits from digital adoptionJuly 2025 Trends & Stepwise Trade Signal Guides - newser.com
Can Atara Biotherapeutics Inc. stock resist market sell offsTrade Volume Report & Risk Controlled Stock Pick Alerts - newser.com
Atara Biotherapeutics Executives Sell Shares for Tax Obligations - TradingView
Is Atara Biotherapeutics Inc. (AT20) stock nearing a technical breakout2025 Pullback Review & Long Hold Capital Preservation Tips - newser.com
Atara Biotherapeutics Inc (ATRA) 財務データ
収益
当期純利益
現金流量
EPS
0.31%
0.33%
大文字化:
|
ボリューム (24 時間):